Somaxon Pharmaceuticals to Present at Lazard Capital Markets 7th Annual Healthcare Conference

SAN DIEGO, Nov 12, 2010 (BUSINESS WIRE) -- Somaxon Pharmaceuticals, Inc.

(NASDAQ: SOMX), a specialty pharmaceutical company, today announced that Richard W. Pascoe, Somaxon's president and chief executive officer, will present at Lazard Capital Markets' 7th Annual Healthcare Conference at the St. Regis Hotel in New York City on Wednesday, November 17, at 10:00 a.m. Eastern Time.

A live webcast of the presentation will be available in the Investor Relations section of the company's Web site under Event Scheduler at The webcast will be archived and accessible for 90 days following the conference.

About Somaxon Pharmaceuticals, Inc.

Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and of late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. Somaxon's product Silenor(R) (doxepin), now available by prescription in the United States, is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance.

For more information, please visit the company's web site at

SOURCE: Somaxon Pharmaceuticals, Inc.

CONTACT: Somaxon Pharmaceuticals, Inc. Tran Nguyen / CFO 858-876-6500 or PondelWilkinson Inc. Rob Whetstone 310-279-5963 Copyright Business Wire 2010 -0- KEYWORD: United States

North America




Professional Services


General Health SUBJECT CODE: Conference